Seven intermittent peritoneal dialysis (IPD) patients were investigated before and after correction of anemia with recombinant human erythropoietin (r-HuEPO). When hematocrit exceeded 300/0, the peritoneal equilibration test was performed at 1, 2, 4, 8 hours.
Correction of anemia was associated with a mean value Increment In creatinine and phosphate clearance In 1 and 2-hour dwells. Differences In clearance of sodium, potassium, and urea In protein loss and glucose absorption before and after r-HuEPO therapy were not statistically significant.
Increased creatinine and phosphate clearance during short dwells can be effected in IPD patients.
EschbachJ., EgrieJ., DowningM.Correction of anemia of end-stage renal disease with recombinant human erythropoietin; results of phase I and II clinical trial.N Engl J Med1987; 310: 73–8.
2.
MacdougallJ., RobertsD., NeubertP.Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.Lancet1989; 1: 425–7.
3.
BoelaertJ., SchurgesM., MathysE.Comparative pharmacokinetics of recombinant human erythropoietin administered by the intravenous routes in continuous peritoneal dialysis patients.Perit Dial Int1989; 9: 95.
4.
NolphK., MillerF., PyleW.An hypothesis to explain the ultrafiltration characteristics of peritoneal dialysis.Kidney Int1981; 20: 543–8.
5.
NolphK., MillerF., RaubinJ.New directions in peritoneal dialysis concepts and applications.Kidney Int1980; 18: 111–16.
6.
ShinabergerJ., MillerJ., GardnerP.Disadvantage and risks of normal hematocrit (Hct) hemodialysis (HD).Kidney Int1989; 35: 264.
7.
ZehnderC.Erythropoietin treatment; influence of hemoglobin concentration on dialyser creatinine clearance in hemodialysed patients.Nephron1989; 51: 424–5.
LowryO., RosenburghJ., FarrA.Protein measurement with the Falin phenol reagent.J Biol Chem1951; 193: 265.
10.
MactierR., KhannaR., TwardowskiZ.Contribution of lymphatic absorption to loose ultrafiltration and solute clearances in continuous ambulatory peritoneal dialysis.J Clin Invest1987; 80: 1311–6.
11.
SteinhauerH.Pharmacological manipulation of peritoneal transport in CAPD.Clin Nephrol1988; 30: 529–33.
12.
GrunzmacherP., ScheurenanE., LoweJ.Correction of renal anaemia by recombinant human erythropoietin. Effects on myocardial function.Contrib Nephrol1988; 66: 176–84.
13.
Lubrich-BirknerJ., SchollonegerP., SteinhauserM.One-year experience with subcutaneous human erythropoietin in CAPD. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto, Peritoneal Dialysis Bulletin Inc., 1990: 302–7.
TwardowskiZ., KsiazekA., MajdanM.Kinetics of continuous ambulatory peritoneal dialysis (CAPD) with four exchanges per day.Clin Nephrol1981; 15: 119–30.
